Mr. Hung-Wen Chen serves as Chairman, Chief Executive Officer, and Director of Apollomics. He brings decades of leadership experience in technology, biotechnology, and pharmaceutical industries, with a proven track record in corporate transformation and strategic growth.

Mr. Chen is the founder and Chairman of Gemtek Technology Co., Ltd., which he built into one of the world’s leading manufacturers of professional wireless broadband equipment with a strong international market presence. He began his career at Taiwan Semiconductor Manufacturing Company (TSMC), where he was engaged in research and development of semiconductor processes and integrated circuits. In recognition of his contributions to the technology industry, he was honored with the Outstanding Alumni Award from National Tsing Hua University in 2010 and the prestigious ERSO Award in 2013.

Mr. Chen also served as Chairman and Chief Executive Officer of Polaris Pharmaceuticals, Inc., where he currently continues as Executive Director. When Polaris faced a severe financial crisis in 2019 due to uncertain clinical trial outcomes and escalating costs, Mr. Chen took decisive leadership to stabilize the company. Under his guidance, Polaris underwent a comprehensive strategic reorganization and achieved a successful turnaround, culminating in its listing on the Taiwan Stock Exchange in June 2022.

Mr. Chen holds a Bachelor’s degree in Physics and a Master’s degree in Electronics Engineering from National Tsing Hua University, Taiwan.

Mr. Yi-Kuei Chen serves as Chief Operating Officer and Director of Apollomics. He brings to the Company over two decades of leadership experience across biotechnology, venture capital, and asset management, with a strong track record in private equity investments and corporate governance.

Mr. Chen is a co-founder of Maxpro Ventures, where his expertise in asset management has led to the successful execution of more than 60 private equity investment transactions across the United States and the Asia-Pacific region. His past investments span a broad range of innovative biotechnology and pharmaceutical companies, including Acepodia, SyneuRx, GenScript, JHL Biotech, Foresee Pharmaceuticals, HEC Pharma, and ACT Genomics Holdings.

Prior to co-founding Maxpro Ventures, Mr. Chen was Senior Director at Integral Group, where he co-led the firm’s Asian transaction process, managed its Shanghai branch, and served on the boards of portfolio companies such as Generon Corporation, FusionVax, Inc., BioLite, Inc., and Flora International Group Co., Ltd. Earlier in his career, from 1999 to 2012, Mr. Chen held senior management positions in the investment division of Central Investment Holdings. During this period, he oversaw a series of successful investments, including Tanox and Biopure, and executed a landmark transaction in 2002 with the acquisition of SEEDNet by New Century InfoComm Tech. He also held board positions at Singfor Life Insurance Company, and CTCI Corporation.

Mr. Chen received an MBA from Syracuse University and an M.S. from the University of Minnesota.

Dr. Chen serves on the Apollomics Board as an independent director since March 2023. Dr. Chen has extensive experiences in therapeutics research and development, regulatory strategy, and company operation. He was the CEO and Chairman of Maxpro Capital Acquisition Corp. which merged with Apollomics in March 2023. He was a managing partner at Maxpro Ventures from 2018 to 2024. Prior to joining Maxpro Ventures, Dr. Chen held management and R&D positions at various biotech companies including SyneuRx International Inc., Meridigen, Celgene, Amcyte, and VivoRx. Currently, he is a director at U-NEURON Biomedical and LaunXP Biomedical.

Dr. Chen received his Ph.D. in Microbiology and Molecular Genetics from Rutgers, The State University of New Jersey and The University of Medicine and Dentistry of New Jersey. He did his postdoctoral training in neuroscience at Caltech.

Mr. Joe Hsueh has served as an independent director of Apollomics since 2025. He brings to the Board over 25 years of experience in operations, finance, and business development across the biopharmaceutical and venture capital industries in Taiwan, China, and the United States.

Mr. Hsueh is currently the President of Anbogen Therapeutics, where he leads finance operations and business development, leveraging his expertise in venture capital and the pharmaceutical sector. Previously, he was the Chief Operating Officer and co-founder of ACT Genomics, where he spearheaded finance operations, sales, marketing, and business development teams to drive strategic growth opportunities.

Earlier in his career, Mr. Hsueh held senior positions at TaiGen Biotechnology in Taiwan, where he successfully led the company through three rounds of financing, co-managed another, and secured a total of USD $114 million within seven years. He also executed an out-licensing agreement and played a key role in expanding business networks within the global pharmaceutical industry. Prior to TaiGen, he worked at Chengxin VC, where he led fundraising efforts for six companies across the U.S. and Taiwan.

Mr. Hsueh holds an MBA from Fairleigh Dickinson University in the United States and a B.A. in Microbiology from Soochow University in Taiwan.

Dr. Jack Jan is a seasoned academic and business leader whose distinguished career spans over three decades across education, international business diplomacy, and corporate strategy.

He is the president and chief consultant of Jan Elite International Co., Ltd., and a consultant of SelectFlorida. He earned his Ph.D. in Mathematics from the University of Louisiana at Lafayette and served as a visiting assistant professor at the University of West Florida, and an associate professor at National Pingtung University, where he founded the Taiwan-U.S. Commercial Forum organized with the American Institute in Taiwan (AIT) to promote international collaboration.

He also served as an independent director of Taiwan listed Gemtek Technology.

Beyond academia, Dr. Jan has been deeply engaged in strengthening Taiwan-U.S. relations and had served as Governor of the American Chamber of Commerce in Kaohsiung. He has received multiple honors, including recognition from the American Institute in Taiwan, the U.S. Department of Commerce, and the U.S. Idaho state government.

Mr. Jerry Tsai has served as an independent director of Apollomics since 2025. He brings to the Board over 25 years of managerial and executive experience in venture capital, industry development, corporate financing, and corporate restructuring.

Mr. Tsai has held senior leadership roles across multiple industries. He previously served as Director of the Strategic Investment Department at the Chairman’s Office of Ting Hsin International Group, where he oversaw target evaluations, mergers and acquisitions, and post-investment management for the group’s strategic investments. Earlier in his career, he was Head of the Industry Support and Promotion Division at the Institute of Information Industry (III) and also served as Project Manager at the Venture Capital Company of Hon Hai Precision Industry (Foxconn).

In addition, Mr. Tsai has played key financial and operational leadership roles in portfolio companies. He served as Chief Financial Officer of Jiangxi Solar PV Company and Suzhou Golden Crown New Energy Company, where he was actively involved in restructuring management teams, enhancing corporate governance, and improving the design and effectiveness of internal control systems. He has also represented both domestic and international investment institutions in supporting the startup and growth of invested companies.

Mr. Tsai holds a bachelor’s degree in Accounting from National Taipei University and a Managerial MBA in Finance from Kent State University.

Mr. Yi-An (Frank) Chu has served as an independent director of Apollomics since 2025. He brings to the Board over 30 years of professional experience across finance, investment, and technology, with deep expertise in corporate finance, investment management, strategic planning, and business operations.

Mr. Chu previously served as Chief Financial Officer of Global Investment Holdings (TWSE: 3701). He has also held senior leadership positions with several major corporate groups, including Compal, VIA Technologies, and Foxconn, where he played key roles in financial strategy, investment execution, and corporate restructuring. Over the course of his career, Mr. Chu has successfully led numerous investment projects and transformation initiatives, demonstrating a strong track record in guiding companies through growth and change.

In addition to his executive roles, Mr. Chu has served as a board director or corporate representative for multiple publicly listed companies, including Yeh-Chiang Technology (TWSE: 6124), GCT Semiconductor (later merged into WIN Semiconductors), Gorilla Technology, and Go TrustID. His broad corporate governance experience underscores his ability to connect financial strategy with operational execution, supporting companies in achieving sustainable development and strategic expansion.

Mr. Chu holds an MBA in Finance and Investment from Baruch College, City University of New York, and a B.S. in Electrical Engineering from National Chiao-Tung University. His unique combination of engineering expertise and financial acumen enables him to navigate both the technical and strategic dimensions of investment and corporate management.